Related references
Note: Only part of the references are listed.Unexpected Thrombocytopenia and Anemia in Cynomolgus Monkeys Induced by a Therapeutic Human Monoclonal Antibody
Nancy Everds et al.
TOXICOLOGIC PATHOLOGY (2013)
Re-challenge with Etanercept in patients with Etanercept-induced Neutropenia
Muhammad Haroon et al.
CLINICAL RHEUMATOLOGY (2012)
Preclinical Safety, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Interleukin-21 in Cynomolgus Macaques (Macaca fascicularis)
Kimberly S. Waggie et al.
INTERNATIONAL JOURNAL OF TOXICOLOGY (2012)
Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients
Alexander J. Thompson et al.
JOURNAL OF HEPATOLOGY (2012)
A predictive biomimetic model of cytokine release induced by TGN1412 and other therapeutic monoclonal antibodies
Vipra Dhir et al.
JOURNAL OF IMMUNOTOXICOLOGY (2012)
Off-Target Platelet Activation in Macaques Unique to a Therapeutic Monoclonal Antibody
Michael J. Santostefano et al.
TOXICOLOGIC PATHOLOGY (2012)
Rat-Specific Decreases in Platelet Count Caused by a Humanized Monoclonal Antibody Against Sclerostin
Daniel G. Rudmann et al.
TOXICOLOGICAL SCIENCES (2012)
Hemolysis upon intravenous immunoglobulin transfusion
Ruth F. Padmore
TRANSFUSION AND APHERESIS SCIENCE (2012)
Changes in expression of membrane TNF, NF-κB activation and neutrophil apoptosis during active and resolved inflammation
Helen L. Wright et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register
Rebecca Davies et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Venous and Arterial Thromboembolic Events in Adalimumab-Treated Patients With Antiadalimumab Antibodies
L. A. Korswagen et al.
ARTHRITIS AND RHEUMATISM (2011)
A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis
Adam Cuker et al.
BLOOD (2011)
Phase I study of LY2469298, an Fc-engineered humanized anti-CD20 antibody, in patients with relapsed or refractory follicular lymphoma
Kensei Tobinai et al.
CANCER SCIENCE (2011)
Thrombotic Microangiopathy with Targeted Cancer Agents
John A. Blake-Haskins et al.
CLINICAL CANCER RESEARCH (2011)
Haematologic toxicities associated with the addition of bevacizumab in cancer patients
Fabio A. B. Schutz et al.
EUROPEAN JOURNAL OF CANCER (2011)
Acute infusion reactions induced by monoclonal antibody therapy
Enrico Maggi et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2011)
Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C
Yasuhito Tanaka et al.
HUMAN MOLECULAR GENETICS (2011)
Etanercept-Induced Lupus Accompanied by Hemophagocytic Syndrome
Daisuke Araki et al.
INTERNAL MEDICINE (2011)
Hematologic toxicities associated with intravenous immunoglobulin therapy
Allison Baxley et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2011)
Hemophagocytosis causes a consumptive anemia of inflammation
Erin E. Zoller et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
Comparison of novel methods for predicting the risk of pro-inflammatory clinical infusion reactions during monoclonal antibody therapy
Lucy Findlay et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2011)
2nd Charles Richet et Jules Hericourt Workshop Therapeutic antibodies and anaphylaxis; May 31-June 1, 2011; Tours, France
Arnaud Daguet et al.
MABS (2011)
Contribution of Surface Localization to Platelet Activation by CD154 Antibodies and Introduction of a Novel Approach for Studying Immune Complex Activity
Meghan Hatfield et al.
THROMBOSIS RESEARCH (2011)
Hemophagocytic Syndrome in a Pancytopenic Simian Retrovirus-Infected Male Rhesus Macaque (Macaca mulatta)
T. M. Cotroneo et al.
VETERINARY PATHOLOGY (2011)
Late-onset neutropenia following rituximab therapy: incidence, clinical features and possible mechanisms
Daniel Tesfa et al.
EXPERT REVIEW OF HEMATOLOGY (2011)
Normal ranges of angiogenesis regulatory proteins in human platelets
Jon E. Peterson et al.
AMERICAN JOURNAL OF HEMATOLOGY (2010)
Rituximab-induced late onset neutropenia in newly-diagnosed B-cell lymphoma correlates with Fc receptor Fc gamma RIIIa 158(V/F) polymorphism
Szu-Chin Li et al.
AMERICAN JOURNAL OF HEMATOLOGY (2010)
Trastuzumab-related thrombocytopenia: always a self-limiting complication?
F. Drudi et al.
ANNALS OF ONCOLOGY (2010)
Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma
F. Morschhauser et al.
ANNALS OF ONCOLOGY (2010)
Sustained IL-4 exposure leads to a novel pathway for hemophagocytosis, inflammation, and tissue macrophage accumulation
Joshua D. Milner et al.
BLOOD (2010)
Bevacizumab induced reversible thrombocytopenia in a patient with recurrent high-grade glioma: a case report
Ticiana Leal et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
US Food and Drug Administration Approval: Ofatumumab for the Treatment of Patients with Chronic Lymphocytic Leukemia Refractory to Fludarabine and Alemtuzumab
Steven J. Lemery et al.
CLINICAL CANCER RESEARCH (2010)
Mapping the Safety Profile of Biologicals A Disproportionality Analysis Using the WHO Adverse Drug Reaction Database, VigiBase
Thijs J. Giezen et al.
DRUG SAFETY (2010)
Comparison of adverse effects related to pegylated interferon-based therapy for patients with chronic hepatitis B and chronic hepatitis C in Taiwan
Jeng-Fu Yang et al.
HEPATOLOGY INTERNATIONAL (2010)
Autoimmune Thrombocytopenic Purpura during Pegylated Interferon alpha Treatment for Chronic Hepatitis C
Soo Ryang Kim et al.
INTERNAL MEDICINE (2010)
Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
William G. Wierda et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Immunoglobulin G Fc Receptor FcγRIIIa 158 V/F Polymorphism Correlates With Rituximab-Induced Neutropenia After Autologous Transplantation in Patients With Non-Hodgkin's Lymphoma
Wen-Kai Weng et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Anti-CD40L Immune Complexes Potently Activate Platelets In Vitro and Cause Thrombosis in FCGR2A Transgenic Mice
Liza Robles-Carrillo et al.
JOURNAL OF IMMUNOLOGY (2010)
Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects
David M. Goldenberg et al.
LEUKEMIA & LYMPHOMA (2010)
The safety and side effects of monoclonal antibodies
Trevor T. Hansel et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Structure-based engineering of a monoclonal antibody for improved solubility
Sheng-Jiun Wu et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2010)
Toxicities of the Thrombopoietic Growth Factors
Adam Cuker
SEMINARS IN HEMATOLOGY (2010)
Thrombocytopenia after abciximab use results from different mechanisms
Sophie Lajus et al.
THROMBOSIS AND HAEMOSTASIS (2010)
Interferon-α induced severe thrombocytopenia: A case report and review of the literature
Li Li et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2010)
Neutropenia in Patients Receiving Anti-Tumor Necrosis Factor Therapy
Richard Hastings et al.
ARTHRITIS CARE & RESEARCH (2010)
Description of the Efficacy and Safety of Three New Biologics in the Treatment of Rheumatoid Arthritis
Steven S. Storage et al.
KOREAN JOURNAL OF INTERNAL MEDICINE (2010)
Rituximab-associated acute thrombocytopenia: An under-diagnosed phenomenon
Ron Ram et al.
AMERICAN JOURNAL OF HEMATOLOGY (2009)
Drug-induced thrombocytopenia induced by trastuzumab: a special challenge in a curable disease
C. Jara Sanchez et al.
ANNALS OF ONCOLOGY (2009)
Severe drug-induced thrombocytopenia after treatment with trastuzumab but not with lapatinib
R. Cathomas et al.
ANNALS OF ONCOLOGY (2009)
Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab
Antonio M. Risitano et al.
BLOOD (2009)
Neutrophils express CD52 and exhibit complement-mediated lysis in the presence of alemtuzumab
Lyn R. Ambrose et al.
BLOOD (2009)
Heparin-Induced Thrombocytopenia A Contemporary Clinical Approach to Diagnosis and Management
Eduard Shantsila et al.
CHEST (2009)
Safety and tolerability of omalizumab
J. Corren et al.
CLINICAL AND EXPERIMENTAL ALLERGY (2009)
Monoclonal antibody-induced cytokine-release syndrome
Peter J. Bugelski et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2009)
Anti-TNFalpha blockers, autoantibodies and autoimmune diseases
Paola Caramaschi et al.
JOINT BONE SPINE (2009)
Humanized Anti-CD20 Antibody, Veltuzumab, in Refractory/Recurrent Non-Hodgkin's Lymphoma: Phase I/II Results
Franck Morschhauser et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase I Trial of Bevacizumab Plus Escalated Doses of Sunitinib in Patients With Metastatic Renal Cell Carcinoma
Darren R. Feldman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Thrombocytopenia associated with the use of anti-tumor necrosis factor-α agents for psoriasis
Alexandra Maria Giovanna Brunasso et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2009)
Are biologics safe in the treatment of atopic dermatitis? A review with a focus on immediate hypersensitivity reactions
Matthew S. Bremmer et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2009)
Heparin-induced thrombocytopenia
A. Greinacher
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2009)
Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice
T. Meyer et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2009)
Disseminated Histiocytic Sarcoma with Excessive Hemophagocytosis in a Cat
Kaori Ide et al.
JOURNAL OF VETERINARY MEDICAL SCIENCE (2009)
Immunogenicity of biologically-derived therapeutics: Assessment and interpretation of nonclinical safety studies
Rafael Ponce et al.
REGULATORY TOXICOLOGY AND PHARMACOLOGY (2009)
Focus on adverse events of tumour necrosis factor α blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients
V. Gerloni et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor α-expressing cells
Hiroki Mitoma et al.
ARTHRITIS AND RHEUMATISM (2008)
Interferon-α2b-induced thrombocytopenia is caused by inhibition of platelet production but not proliferation and endomitosis in human megakaryocytes
Akiko Yamane et al.
BLOOD (2008)
Rituximab-Induced Severe Acute Thrombocytopenia: A case Report and Review of Literature
Suneel Dhand et al.
CANCER INVESTIGATION (2008)
Severe thrombocytopenia induced by a single infusion of trastuzumab
Omi Parikh et al.
CLINICAL BREAST CANCER (2008)
Hypersensitivity Reactions to Last Generation Chimeric, Umanized and Human Recombinant Monoclonal Antibodies for Therapeutic Use
G. Calogiuri et al.
CURRENT PHARMACEUTICAL DESIGN (2008)
Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin
M. G. Antonini et al.
INFECTION (2008)
Preclinical Safety and Pharmacology of an Anti-Human Interleukin-13 Monoclonal Antibody in Normal Macaques and in Macaques with Allergic Asthma
Pauline L. Martin et al.
INTERNATIONAL JOURNAL OF TOXICOLOGY (2008)
Complement activation plays a key role in antibody-induced infusion toxicity in monkeys and rats
Tomonori Tawara et al.
JOURNAL OF IMMUNOLOGY (2008)
Hemophagocytic syndrome in an adolescent with Crohn disease receiving azathioprine and infliximab
Karen A. Francolla et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2008)
Platelet pro-aggregatory effects of CD40L monoclonal antibody
Maribel Mirabet et al.
MOLECULAR IMMUNOLOGY (2008)
Lymphocyte subpopulation imbalances, bone marrow hematopoiesis and histopathology in rituximab-treated lymphoma patients with late-onset neutropenia
K. Stamatopoulos et al.
LEUKEMIA (2008)
Platelet-associated IgG for the diagnosis of immune thrombocytopaenic purpura during peginterferon alpha and ribavirin treatment for chronic hepatitis C
Masaru Enomoto et al.
LIVER INTERNATIONAL (2008)
Late-onset neutropenia associated with rituximab therapy: evidence for a maturation arrest at the (pro)myelocyte stage of granulopoiesis
Daniel Tesfa et al.
MEDICAL ONCOLOGY (2008)
VEGF inhibition and renal thrombotic microangiopathy
Vera Eremina et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1,3-galactose
Christine H. Chung et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Managing premedications and the risk for reactions to infusional monoclonal antibody therapy
Christine H. Chung
ONCOLOGIST (2008)
Epoetin-associated pure red cell aplasia: past, present, and future considerations
June M. McKoy et al.
TRANSFUSION (2008)
Infusion Reactions Triggered by Monoclonal Antibodies Treating Solid Tumors
Pamela H. Carney et al.
JOURNAL OF INFUSION NURSING (2008)
Three significant cases of neutropenia with etanercept
C. Wenham et al.
RHEUMATOLOGY (2008)
Mechanism of action of certolizumab pegol (CDP870): In vitro comparison with other anti-tumor necrosis factor at agents
Andrew Nesbitt et al.
INFLAMMATORY BOWEL DISEASES (2007)
Direct antiglobulin test negative autoimmune haemolytic anaemia associated with fludarabine/cyclophosphamide/rituximab therapy
George Garratty et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer
C. Kut et al.
BRITISH JOURNAL OF CANCER (2007)
Efalizumab-associated thrombocytopenia
Sarah Grim Hostetler et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2007)
Platelets take up the monoclonal antibody bevacizumab
Henk M. W. Verheu et al.
CLINICAL CANCER RESEARCH (2007)
High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history
Bert H. O'Neil et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab
Frank A. Scappaticci et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Current concepts - Drug-induced immune thrombocytopenia
Richard H. Aster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Drug-induced thrombocytopenia
Glan Paolo Visentin et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2007)
Infliximab and adalimumab-induced thrombocytopenia in a woman with colonic Crohn's disease
Antonio Salar et al.
GUT (2007)
Red cell aplasia and autoimmune hemolytic anemia following immunosuppression with alemtuzumab, mycophenolate, and daclizumab in pancreas transplant recipients
Milena Elimelakh et al.
HAEMATOLOGICA (2007)
Hemophagocytic syndrome in dogs: 24 cases (1996-2005)
Douglas J. Weiss
JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION (2007)
Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis
C. J. van der Laken et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Late-onset neutropenia following rituximab results from a hematopoietic lineage competition due to an excessive BAFF-induced B-cell recovery
B. Terrier et al.
HAEMATOLOGICA (2007)
Glycoprotein IIb/IIIa inhibitor-induced thrombocytopenia -: Diagnosis and treatment
S. M. Said et al.
CLINICAL RESEARCH IN CARDIOLOGY (2007)
Animal models of complement-mediated hypersensitivity reactions to liposomes and other lipid-based nanoparticles
Janos Szebeni et al.
JOURNAL OF LIPOSOME RESEARCH (2007)
Toxicity as a result of immunostimulation by biologics
Elizabeth J. Gribble et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2007)
Healthy animals and animal models of human disease(s) in safety assessment of human pharmaceuticals, including therapeutic antibodies
Rakesh Dixit et al.
DRUG DISCOVERY TODAY (2007)
Management and preparedness for infusion and hypersensitivity reactions
Heinz-Josef Lenz
ONCOLOGIST (2007)
Infusion reactions and their management
Lloyd Mayer et al.
GASTROENTEROLOGY CLINICS OF NORTH AMERICA (2006)
Platelet FcγRIIA binds and internalizes IgG-containing complexes
Randall G. Worth et al.
EXPERIMENTAL HEMATOLOGY (2006)
Efalizumab-induced autoimmune pancytopenia
W. L. Tom et al.
BRITISH JOURNAL OF DERMATOLOGY (2006)
Late-onset neutropenia in patients treated with rituximab for non-Hodgkin's lymphoma
Kenji Fukuno et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2006)
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412
Ganesh Suntharalingam et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Autoimmune thrombocytopenia induced by PEG-IFN-α plus ribavirin in hepatitis C
Nese Demirturk et al.
PLATELETS (2006)
Problems encountered during anti-tumour necrosis factor therapy
Sheetal B. Desai et al.
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY (2006)
Adverse effects of the humanized antibodies used as cancer therapeutics
Jean Klastersky
CURRENT OPINION IN ONCOLOGY (2006)
Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis
GJ Wolbink et al.
ARTHRITIS AND RHEUMATISM (2006)
Late onset autoimmune thrombocytopenia associated with pegylated interferon-α-2b plus ribavirin treatment for chronic hepatitis C
IS Elefsiniotis et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2006)
Complement activation-related pseudoallergy: A new class of drug-induced acute immune toxicity
J Szebeni
TOXICOLOGY (2005)
Immune thrombocytopenia associated with efalizumab therapy for psoriasis
TE Warkentin et al.
ANNALS OF INTERNAL MEDICINE (2005)
B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis
K Dunleavy et al.
BLOOD (2005)
Severe and prolonged myeloid haematopoietic toxicity with myelodysplastic features following alemtuzumab therapy in patients with peripheral T-cell lymphoproliferative disorders
SDJ Gibbs et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Profound thrombocytopenia associated with tirofiban - Case report and review of literature
S Patel et al.
ANGIOLOGY (2005)
Platelet activation leads to activation and propagation of the complement system
I del Conde et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Hematologic side effects of interferon and ribavirin therapy
KV Kowdley
JOURNAL OF CLINICAL GASTROENTEROLOGY (2005)
In vivo platelet redistribution and acute transient thrombocytopenia after eptifibatide injection in baboons
KA Tanaka et al.
THROMBOSIS RESEARCH (2005)
A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas
G Enblad et al.
BLOOD (2004)
Final results of the ReoPro Readministration Registry
JP Dery et al.
AMERICAN JOURNAL OF CARDIOLOGY (2004)
Efficacy and safety of ABI793, a novel human antihuman CD154 monoclonal antibody, in cynomolgus monkey renal allotransplantation
W Schuler et al.
TRANSPLANTATION (2004)
Possible autoimmune thrombocytopenia associated with pegylated interferon-alpha 2a plus ribavarin treatment for hepatitis C
BC Medeiros et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2004)
Severe autoimmune thrombocytopenic purpura during interferon-alpha therapy for chronic myelogenous leukemia
K Arimura et al.
ACTA HAEMATOLOGICA (2004)
Delayed-type hypersensitivity reaction or serum sickness after rituximab treatment
B Hellerstedt et al.
ANNALS OF ONCOLOGY (2003)
Application of the CFU-GM assay to predict acute drug-induced neutropenia: An international blind trial to validate a prediction model for the maximum tolerated dose (MTD) of myelosuppressive xenobiotics
A Pessina et al.
TOXICOLOGICAL SCIENCES (2003)
Bevacizumab, bleeding, thrombosis, and warfarin
S Kilickap et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Preclinical safety of recombinant human interleukin-18
DJ Herzyk et al.
TOXICOLOGIC PATHOLOGY (2003)
Anaphylactic shock caused by immunoglobulin E sensitization after retreatment with the chimeric anti-interleukin-2 receptor monoclonal antibody basiliximab
V Baudouin et al.
TRANSPLANTATION (2003)
Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome
J Lundin et al.
BLOOD (2003)
Delayed-onset neutropenia associated with rituximab therapy
K Chaiwatanatorn et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Recombinant human macrophage colony-stimulating factor-induced thrombocytopenia in dogs
K Abrams et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis
DT Boumpas et al.
ARTHRITIS AND RHEUMATISM (2003)
Severe autoimmune cytopenias in treatment-naive hepatitis C virus infection -: Clinical description of 35 cases
M Ramos-Casals et al.
MEDICINE (2003)
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease
F Baert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Severe autoimmune hemolytic anemia following rituximab therapy in a patient with a lymphoproliferative disorder
E Jourdan et al.
LEUKEMIA & LYMPHOMA (2003)
Aplastic anemia following administration of a tumor necrosis factor-alpha inhibitor
J Kuruvilla et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2003)
Recombinant human thrombopoietin: basic biology and evaluation of clinical studies
DJ Kuter et al.
BLOOD (2002)
Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C
A Soza et al.
HEPATOLOGY (2002)
Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide
SP Henry et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2002)
Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor
RL Basser et al.
BLOOD (2002)
Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets
BR Curtis et al.
BLOOD (2002)
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene
G Cartron et al.
BLOOD (2002)
Autoimmune thrombocytopenia induced by PEG-IFN-alpha(2b) plus ribavirin in hepatitis C
A Sagir et al.
DIGESTIVE DISEASES AND SCIENCES (2002)
In vivo neutralization of TNF-α promotes humoral autoimmunity by preventing the induction of CTL
CS Via et al.
JOURNAL OF IMMUNOLOGY (2001)
Thrombocytopenia caused by the development of antibodies to thrombopoietin
JZ Li et al.
BLOOD (2001)
Anaphylactic reactions to aprotinin reexposure in cardiac surgery -: Relation to antiaprotinin immunoglobulin G and E antibodies
W Dietrich et al.
ANESTHESIOLOGY (2001)
Tumor necrosis factor-α blockade in the treatment of rheumatoid arthritis
EC Keystone
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA (2001)
Severe delayed thrombocytopenia associated with abciximab (ReoPro) therapy
MS Reddy et al.
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS (2001)
Drug-induced thrombotic microangiopathy - Incidence, prevention and management
R Pisoni et al.
DRUG SAFETY (2001)
Interleukin 10-induced thrombocytopenia in normal healthy adult volunteers: evidence for decreased platelet production
JA Sosman et al.
BRITISH JOURNAL OF HAEMATOLOGY (2000)
Concordance of the toxicity of pharmaceuticals in humans and in animals
H Olson et al.
REGULATORY TOXICOLOGY AND PHARMACOLOGY (2000)
Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: Bleeding, reversal, thrombocytopenia, and retreatment
JE Tcheng
AMERICAN HEART JOURNAL (2000)
Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand
T Kawai et al.
NATURE MEDICINE (2000)
Impact on T-cell depletion and CD34(+) cell recovery using humanised CD52 monoclonal antibody (CAMPATH-1H) in BM and PSBC collections; comparison with CAMPATH-1M and CAMPATH-1G
RJ Williams et al.
CYTOTHERAPY (2000)
Share Paper
